M&A activity
13 stories
Abbott’s newly acquired oncology diagnostics from Exact Sciences—Cologuard and Oncotype DX—are offsetting COVID testing declines and powering a Q2 earnings beat. The company lifted its full-year 2026 adjusted EPS target, highlighting the value of high-margin, recurring precision testing businesses.
As Bupa moves to acquire Partnered Health, a cyberattack on 21 clinics exposes the vulnerability of real-world health data that biotech and pharma firms increasingly rely on for research. The breach of longitudinal patient records — including pathology and referral data — illustrates the cybersecurity risks inherent in consolidating clinical datasets for drug development and personalized medicine.
For the biotech world, the 23andMe saga is a stark lesson: acquiring assets out of bankruptcy does not shield from inherited data-breach liabilities. Anne Wojcicki’s $305 million purchase now carries a $46.75 million settlement that could chill future investments in consumer genomics.
Repligen’s reported interest in Biolife Solutions could create a bioprocessing-to-cryopreservation powerhouse. For the biotech industry, this deal promises an integrated supplier but raises concerns about supplier consolidation as the cell and gene therapy market expands at over 20% CAGR.
The biotech sector sees heightened M&A activity as H.B. Fuller acquires UK tissue-repair specialist AMS for £659M. The all-cash deal brings a branded pipeline of cyanoacrylate surgical adhesives and alginate wound dressings under industrial ownership, with immediate earnings accretion.
A $31.3 million impairment on the Fabric Genomics deal has drawn a securities lawsuit against GeneDx. For biotech investors, the case highlights the perils of overvalued AI acquisitions in genomics, as GeneDx trimmed its revenue forecast by up to $80 million.
UID's acquisition of AEG ID, a participant in ISO animal identification standards, adds capacity for tens of millions of RFID transponders annually, targeting livestock and pet identification markets in North America and Europe.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising allosteric BCR-ABL inhibitor for leukemia. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug, Keytruda.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion in cash, a strategic move to diversify its oncology pipeline. The deal centers on Terns' promising leukemia candidate, TERN-701, as Merck prepares for the 2028 patent expiration of its blockbuster immunotherapy, Keytruda.
Wellgistics Health Inc. has entered into a non-binding Letter of Intent to acquire Neuritek Therapeutics for $105 million. The deal marks a significant strategic pivot for Wellgistics into the high-growth neurological and psychiatric drug development sector.
Novartis AG has entered into an agreement to acquire SNV4818, an experimental breast cancer drug from Synnovation Therapeutics, in a deal valued at up to $3 billion. This strategic move aims to strengthen Novartis's leadership in the oncology sector as it seeks to replenish its pipeline with high-potential targeted therapies.
Aster DM Healthcare has cleared a major regulatory hurdle as shareholders and creditors overwhelmingly approved its merger with Quality Care India Limited (QCIL). The deal is set to create one of India’s largest hospital chains, significantly expanding Aster's domestic footprint following its strategic separation from its Gulf operations.
Scantox has acquired the DuplexSeq™ nonclinical genomics safety business from TwinStrand Biosciences, integrating ultra-sensitive sequencing technology into its pre-clinical service suite. This strategic move positions Scantox as a leader in high-resolution genetic toxicology, offering pharmaceutical clients unprecedented accuracy in identifying mutagenic risks.
According to our own tracking database, this category has accumulated 13 acquisitions stories since coverage began. This page aggregates the latest acquisitions stories within our biotech coverage area. Every story is cross-referenced across multiple primary sources, scored for sentiment and operational impact, and timestamped so fresh developments surface first. We track m&a activity and surface the angles a domain expert would actually read.
Story selection follows our editorial methodology — impact scoring weights regulatory, financial, and operational developments distinctly. Sentiment is classified across five tiers via supervised classification trained on labeled industry corpora. See our glossary for term definitions and our trends index for longitudinal patterns across the biotech beat.
| Signal | What it tells you |
|---|---|
| Verified by N sources | Confidence the story isn't a single-source rumor — N≥2 means the development is independently corroborated. |
| Impact score (1-10) | Estimated regulatory, financial, or operational impact. 8+ indicates a story experienced operators should act on. |
| Sentiment | Five-tier classification (very bullish through very bearish) trained on labeled biotech-specific corpora. |
| Time stamp | Recency. Fresh stories (under 1h) render with a highlighted timestamp; stale stories (≥24h) render dimmed. |